/
Oncology
Advanced Solid Malignancies
29
Pipeline Programs↗
20
Active Trials↗
37
Companies Involved↗
Advanced Solid Malignancies is an emerging landscape with 29 programs across 37 companies. The most active players are Kumquat Biosciences Inc., AstraZeneca, Treadwell Therapeutics, Inc.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 112
Phase 210
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
20 of 29 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.
Analysis
Trial Status
97
clinical trials
Completed52 · 54%
Terminated17 · 18%
Recruiting13 · 13%
Unknown status6 · 6%
Active, not recruiting6 · 6%
Suspended2 · 2%
Other1 · 1%
Clinical Trials
Trial Activity
97 trials
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)